Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
Andreas TrojanSven RothZiad AtassiMichael KiesslingReinhard ZenhaeusernYannick KadvanyJohannes SchumacherGerd A Kullak-UblickMatti AaproAlexandru E EniuPublished in: JMIR cancer (2024)
ClinicalTrials.gov NCT05234021; https://clinicaltrials.gov/study/NCT05234021.